Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen | Zendy

Paul E. Goss | Zendy; James N. Ingle | Zendy; Joseph L. Pater | Zendy; Silvana Martino | Zendy; Nicholas J. Robert | Zendy; Hyman B. Muss | Zendy; Martine Piccart | Zendy; Monica Castiglione | Zendy; Lois E. Shepherd | Zendy; Kathleen I. Pritchard | Zendy; Robert B. Livingston | Zendy; Nancy E. Davidson | Zendy; Larry Norton | Zendy; Edith A. Perez | Zendy; Jeffrey S. Abrams | Zendy; David Cameron | Zendy; Michael Palmer | Zendy; Dongsheng Tu | Zendy

Open Access

Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen

Author(s) -

Paul E. Goss,

James N. Ingle,

Joseph L. Pater,

Silvana Martino,

Nicholas J. Robert,

Hyman B. Muss,

Martine Piccart,

Monica Castiglione,

Lois E. Shepherd,

Kathleen I. Pritchard,

Robert B. Livingston,

Nancy E. Davidson,

Larry Norton,

Edith A. Perez,

Jeffrey S. Abrams,

David Cameron,

Michael Palmer,

Dongsheng Tu

Publication year - 2008

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2007.11.6798

Subject(s) - medicine , letrozole , tamoxifen , hazard ratio , breast cancer , cohort , gynecology , cancer , oncology , confidence interval

The National Cancer Institute of Canada Clinical Trials Group MA.17 trial examined the efficacy of letrozole (LET) started within 3 months of 5 years of adjuvant tamoxifen in postmenopausal hormone receptor-positive early-stage breast cancer. When the trial was unblinded, patients who received placebo (PLAC) were offered LET.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research